secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2022-07-22T23:59:59+00:00
Accession:  0001213900-22-040769
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 3.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larkspur Health Acquisition Corp. announces business combination with ZyVersa Therapeutics and $7M private placement
--------------------------------------------------------------------------------

- SPAC Larkspur (LSPR) entered into Business Combination Agreement with ZyVersa Therapeutics, a clinical-stage biopharma targeting renal and inflammatory diseases.
- Private placement of approximately $7.0M in Convertible Preferred shares and warrants to fund the deal, subject to additional interim financing and Nasdaq listing.
- Closing deadline set for December 15, 2022; transaction requires shareholder approval and other customary conditions.
- ZyVersa will survive as a wholly owned subsidiary; combined company expected to be named ZyVersa Therapeutics.
- Company warrants and options assumed and converted into SPAC equity; key shareholders enter lock-up and support agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000121390022040769/0001213900-22-040769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000121390022040769/ea163113-8k425_larkspur.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-040769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer